In Focus: lung cancer

Over the past years, there have been great advancements in the field of lung cancer; with the success we have seen with immunotherapy drugs such as Keytruda for non-small cell lung cancer and Tecentriq for extensive small-cell lung cancer. However, there are still big strides that need to be made in the field. In this feature we will be exploring the current understanding of the diagnosis, treatment and management of lung cancer.

Articles

The Lung Ambition Alliance: breaking through limits, together

OCTALKS l Breaking through limits in lung cancer survival with Patrick Connor

Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC: updated analysis of the observational GioTag study

How can better identification of T790M help to inform treatment sequencing decisions in EGFR mutation-positive NSCLC?

Pembrolizumab for small-cell lung cancer: an interview with Hyun Cheol Chung

I-O Optimise: a multinational program providing real-world insights into lung cancer management

Lung Cancer Ambition Alliance with Giorgio Scagliotti

In Focus: lung cancer

Tumor clonality and resistance mechanisms in EGFR mutation-positive NSCLC: implications for therapeutic sequencing